Results 31 to 40 of about 13,784 (200)
Frontiers in Pharmacology, 2021 Ovarian cancer is the second most common gynecological malignancy, and one of the most deadly. The bottleneck restricting the treatment of ovarian cancer is its multi-drug resistance to chemotherapy.
Ming Sui +7 more
doaj +1 more source
LncRNA DLEU2 contributes to Taxol resistance of gastric cancer cells through regulating the miR-30c-5p-LDHA axis [PDF]
, 2023 Gastric cancer (GC) is a human malignancy which is associated with high mortality rate and poor prognosis. In addition to surgery, chemo- and radio-therapies are effective strategies against GC at advanced or metastatic stage.
Haijun Li (290756) +2 more
core +1 more source
Development of taxane resistance in a panel of human lung cancer cell lines [PDF]
, 2008 Using a selection process designed to reflect clinically relevant conditions, a panel of taxane-selected variants were developed to study further the mechanisms of resistance in lung cancer.
Keenan, Joanne +3 more
core +1 more source
Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells [PDF]
Brazilian Journal of Medical and Biological ResearchAlthough Taxol has improved the survival of cancer patients as a first-line chemotherapeutic agent, an increasing number of patients develop resistance to Taxol after prolonged treatment.
Ying Shi +4 more
doaj +2 more sources
PLoS ONE, 2023 ObjectiveBreast cancer is the most common and high-incidence cancer in women. It is mainly treated by surgery combined with chemoradiation. The main challenge in treating breast cancer patients is developing resistance to chemotherapeutics, so it is ...
Weihua Gong +3 more
doaj +1 more source
European review for medical and pharmacological sciences, 2021 Nasopharyngeal carcinoma (NPC) is a common cancer with high incidence in Southern China. Taxol is one of the first-line chemotherapeutic drugs for treating NPC; however, Taxol resistance has become the main difficulty for clinical treatment and the mechanisms remain not fully understood. In this study, we mainly focus on exploring whether exosomes from
Yuan, F., Zhou, Z.-F.
openaire +2 more sources
Abstract 2109: Mir-125b confers the resistance of cancer cells to Taxol through suppression of Bak1 [PDF]
, 2010 Paclitaxel (Taxol) is one of the most effective chemotherapeutic agents for treatment of cancer patients. Despite impressive initial clinical responses, the majority of patients will eventually develop some degree of resistance to Taxol-based therapy ...
Ming Zhou +11 more
core +1 more source
Abstract 1809: Reversal of Taxol resistance in ovarian cancer cell lines by IGF pathway inhibition [PDF]
, 2010 Our group recently reported increased insulin-like growth factor 2 (IGF2) expression and AKT activation in ovarian cancer cells following treatment with the microtubule-stabilizing agent Taxol. We hypothesized that IGF2 is a modulator of Taxol resistance.
Gloria S. Huang +2 more
core +1 more source
Perturbations in 3D genome organization can promote acquired drug resistance
Cell Reports, 2023 Summary: Acquired drug resistance is a major problem in the treatment of cancer. hTERT-immortalized, untransformed RPE-1 cells can acquire resistance to Taxol by derepressing the ABCB1 gene, encoding for the multidrug transporter P-gP.
Anna G. Manjón +17 more
doaj +1 more source
A Compressive Review about Taxol®: History and Future Challenges
Molecules, 2020 Taxol®, which is also known as paclitaxel, is a chemotherapeutic agent widely used to treat different cancers. Since the discovery of its antitumoral activity, Taxol® has been used to treat over one million patients, making it one of the most widely ...
Julia Gallego-Jara +4 more
doaj +1 more source